ArticleImmunotherapy2011
Cellular immunotherapy for high-grade glioma.
Article in Immunotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02653196 (A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.Oncogene · 2018Review
- Integrating the glioblastoma microenvironment into engineered experimental models.Future science OA · 2017Review
- Insights into molecular therapy of glioma: current challenges and next generation blueprint.Acta pharmacologica Sinica · 2017Review
- Immunological low-dose radiation modulates the pediatric medulloblastoma antigens and enhances antibody-dependent cellular cytotoxicity.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2017Article
- Cancer Immunotherapy for Gliomas: Overview and Future Directions.Neurologia medico-chirurgica · 2016Review
- Stereotaxic administrations of allogeneic human Vγ9Vδ2 T cells efficiently control the development of human glioblastoma brain tumors.Oncoimmunology · 2016Article
- Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- Combining immunotherapy with radiation for the treatment of glioblastoma.Journal of neuro-oncology · 2015Review
- T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.Cytotherapy · 2014Article
- Glioblastoma multiforme: State of the art and future therapeutics.Surgical neurology international · 2014Review
- Human cytomegalovirus antigens in malignant gliomas as targets for adoptive cellular therapy.Frontiers in oncology · 2014Review
- Current vaccine trials in glioblastoma: a review.Journal of immunology research · 2014Review
- Article
- Glioblastoma cancer stem-like cells: implications for pathogenesis and treatment.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The outcome for patients with the most common primary brain tumor, glioblastoma multiforme (GBM), remains poor. Several immunotherapeutic approaches are actively being pursued including antibodies and cell-based therapies. While the blood-brain barrier protects brain tumor cells from therapeutic antibodies, immune cells have the ability to traverse the blood-brain barrier and migrate into GBM tumors to exert their therapeutic function. Results of Phase I clinical studies with vaccines to induce GBM-specific T cells are encouraging and Phase II clinical trials are in progress. Nonvaccine-based cell therapy for GBM has been actively explored over the last four decades. Here we will review past clinical experience with adoptive cell therapies for GBM and summarize current strategies on how to improve these approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.